Last reviewed · How we verify
NCT04374123
COVID-19 Serology Screening and Strict Protocol in the Endoscopy Unit
trial testing Serological screening for IgG and IgM antibodies against COVID-19 in COVID in 111 participants. Completed in 15 June 2020.
20 May 2020
Quick facts
| Lead sponsor | Instituto Ecuatoriano de Enfermedades Digestivas |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 111 |
| Start date | 20 April 2020 |
| Primary completion | 20 May 2020 |
| Estimated completion | 15 June 2020 |
| Sites | 1 location across Ecuador |
Drugs / interventions tested
- Serological screening for IgG and IgM antibodies against COVID-19
Conditions studied
- COVID — all drugs for COVID →
Sponsor
Instituto Ecuatoriano de Enfermedades Digestivas — full company profile →
Who can join
Adults 18 to 80, any sex, with COVID. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The novel COronaVIrus Disease 19 (COVID-19) outbreak has impacted daily activities in nearly 210 countries and territories worldwide. In Ecuador, the city of Guayaquil has nearly two-thirds of the COVID-positive patients in the country and nearly 40% of infected individuals are health-care related personnel. Nonemergent, emergent and urgent endoscopic procedures are necessary to be performed during the COVID-19 pandemic. Several experiences in the management of the endoscopic unit during the pandemic has been proposed. We aimed to prospectively evaluate a strict protocol for preventing potential nosocomial infection of COVID-19.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04374123
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID
Currently open trials in the same condition.
- NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
- NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
- NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
- NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
- NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting
Other Instituto Ecuatoriano de Enfermedades Digestivas trials
Trials by the same sponsor.
- NCT05453292 — Endoscopic Ultrasound Radiofrequency Ablation for GISTs · NA · unknown
- NCT06298604 — Motorized Fine Needle Biopsy vs Standard Needles · NA · unknown
- NCT06264466 — Safety and Efficacy of a Novel Flexible Bipolar in POEM · NA · unknown
- NCT06102980 — Endoscopic Ultrasound Shear Wave for Liver Fibrosis in MASLD Patients: The RUMIPAMBA Trial · NA · recruiting
- NCT06038201 — Cholecystectomy vs EUS-guided GBD With Stone Removal · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04374123 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto Ecuatoriano de Enfermedades Digestivas
- Last refreshed: 28 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04374123.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing